Reimbursement Review Reports


( Last Updated : October 2, 2022)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Adlyxine lixisenatide Diabetes mellitus, Type 2 Reimburse with clinical criteria and/or conditions Complete
Admelog Insulin lispro Cancelled
Adtralza tralokinumab atopic dermatitis Do not reimburse Complete
Aduhelm aducanumab Alzheimer’s disease Withdrawn
Advicor Niacin/lovastatin Hypercholesterolemia and mixed dyslipidemia List Complete
Aermony RespiClick fluticasone propionate Asthma Reimburse with clinical criteria and/or conditions Complete
Afinitor Everolimus Neuroendocrine tumors (NET) of Gastrointestinal or Lung origin Reimburse with clinical criteria and/or conditions Complete
Afinitor Everolimus Pancreatic Neuroendocrine Tumour Reimburse with clinical criteria and/or conditions Complete
Afinitor Everolimus Advanced Breast Cancer Reimburse with clinical criteria and/or conditions Complete
Afinitor Everolimus Renal angiomyolipoma associated with tuberous sclerosis complex (TSC) Do not list Complete